Stoke Therapeutics

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell STOK and other ETFs, options, and stocks.

About STOK

Stoke Therapeutics, Inc. is a biotechnology company, which engages in the research and development of treatments for genetic diseases. It offers a wide range of relevant tissues including the central nervous system, eye, kidney, and liver. 

CEO
Ian Frederick Smith
CEOIan Frederick Smith
Employees
170
Employees170
Headquarters
Bedford, Massachusetts
HeadquartersBedford, Massachusetts
Founded
2014
Founded2014
Employees
170
Employees170

STOK Key Statistics

Market cap
1.84B
Market cap1.84B
Price-Earnings ratio
-221.35
Price-Earnings ratio-221.35
Dividend yield
Dividend yield
Average volume
905.11K
Average volume905.11K
High today
$33.00
High today$33.00
Low today
$30.55
Low today$30.55
Open price
$32.85
Open price$32.85
Volume
559.65K
Volume559.65K
52 Week high
$40.22
52 Week high$40.22
52 Week low
$5.35
52 Week low$5.35

Stock Snapshot

With a market cap of 1.84B, Stoke Therapeutics(STOK) trades at $31.07. The stock has a price-to-earnings ratio of -221.35.

During the trading session on 2026-03-18, Stoke Therapeutics(STOK) shares reached a daily high of $33.00 and a low of $30.55. At a current price of $31.07, the stock is +1.7% higher than the low and still -5.9% under the high.

Trading volume for Stoke Therapeutics(STOK) stock has reached 559.65K, versus its average volume of 905.11K.

Over the past 52 weeks, Stoke Therapeutics(STOK) stock has traded between a high of $40.22 and a low of $5.35.

Over the past 52 weeks, Stoke Therapeutics(STOK) stock has traded between a high of $40.22 and a low of $5.35.

STOK News

Simply Wall St 2d
Why Stoke Therapeutics Is Down 11.4% After NEJM Data on Dravet Syndrome Drug - And What's Next

In March 2026, Stoke Therapeutics and Biogen reported New England Journal of Medicine data showing that investigational antisense therapy zorevunersen produced...

Why Stoke Therapeutics Is Down 11.4% After NEJM Data on Dravet Syndrome Drug - And What's Next

Analyst ratings

100%

of 12 ratings
Buy
100%
Hold
0%
Sell
0%

People also own

Based on the portfolios of people who own STOK. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.